GYRE THERAPEUTICS, INC.

8-K · ef20075381_8k.htm iXBRL

0001124105 2026-06-01 2026-06-01

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

 FORM 8-K

 CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of report (Date of earliest event reported): June 1, 2026

 Gyre Therapeutics, Inc.

 (Exact name of registrant as specified in its charter)

 Delaware

 000-51173

 56-2020050

 (State or other jurisdiction of incorporation)

 (Commission File Number)

 (IRS Employer Identification No.)

 12730 High Bluff Drive

 Suite 250

 San Diego , CA

  

 92130

 (Address of principal executive offices)

  

 (Zip Code)

 Registrant’s telephone number, including area code: ( 858 ) 284-0115

 N/A

 (Former name or former address, if changed since last report)

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
 following provisions ( see General Instruction A.2. below):

 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class

  

 Trading Symbol(s)

  

 Name of each exchange on which

 registered

 Common Stock

  

 GYRE

  

 The Nasdaq Capital Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
 chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 Emerging growth company ☐

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
 or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Item 7.01

 Regulation FD Disclosure.

  

 On June 1, 2026, Gyre Therapeutics, Inc. (the “Company”) made available an updated corporate presentation on the Company’s website.

  

 A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit
 furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
 section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

  

 Item 9.01

 Financial Statements and Exhibits.

  

 (d) Exhibits .

  

 EXHIBIT INDEX

 Exhibit

 No.

 Description

  

  

 99.1

 Corporate Presentation, dated June 2026

  

  

 104

 Cover page interactive data file (embedded within the inline XBRL document)

 SIGNATURE

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
 behalf by the undersigned hereunto duly authorized.

  

 GYRE THERAPEUTICS, INC.

  

  

 Date: June 2, 2026

 By:

 /s/ Thomas Eastling

  

 Name:

 Thomas Eastling

  

 Title:

 Chief Financial Officer